Genotropin + Placebo
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Brain Injuries
Conditions
Brain Injuries, Growth Hormone Deficiency
Trial Timeline
Mar 1, 2008 → Jan 1, 2009
NCT ID
NCT00555009About Genotropin + Placebo
Genotropin + Placebo is a approved stage product being developed by Pfizer for Brain Injuries. The current trial status is terminated. This product is registered under clinical trial identifier NCT00555009. Target conditions include Brain Injuries, Growth Hormone Deficiency.
What happened to similar drugs?
4 of 17 similar drugs in Brain Injuries were approved
Approved (4) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00555009 | Approved | Terminated |
Competing Products
20 competing products in Brain Injuries
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 39 |
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 27 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 32 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 27 |
| filgrastim + exatecan mesylate | Daiichi Sankyo | Phase 1 | 29 |
| Eribulin Mesylate | Eisai | Phase 1 | 29 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 42 |
| Palonosetron (Aloxi) and Dexamethasone | Eisai | Phase 2 | 27 |
| GLIADEL | Eisai | Phase 2 | 35 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 40 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 40 |
| Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim | Eli Lilly | Phase 1 | 29 |
| abemaciclib + abemaciclib | Eli Lilly | Phase 2 | 39 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 27 |
| ABT-888 | AbbVie | Phase 1 | 29 |
| Veliparib + Placebo | AbbVie | Phase 2 | 35 |
| Iressa (Gefitinib) | AstraZeneca | Phase 2 | 27 |
| Trastuzumab deruxtecan | AstraZeneca | Phase 2 | 42 |
| Exenatide | AstraZeneca | Approved | 43 |
| AZD5213 | AstraZeneca | Phase 1 | 29 |